| Literature DB >> 36059674 |
Xue-Fei Liu1, Bi-Cong Yan1,2, Ying Li1, Feng-Hua Ma3, Jin-Wei Qiang1.
Abstract
Background: The presence of lymphovascular space invasion (LVSI) has been demonstrated to be significantly associated with poor outcome in endometrial cancer (EC). No effective clinical tools could be used for the prediction of LVSI preoperatively in early-stage EC. A radiomics nomogram based on MRI was established to predict LVSI in patients with early-stage EC.Entities:
Keywords: endometrial cancer; lymphovascular space invasion (LVSI); magnetic resonance imaging; nomogram; radiomics
Year: 2022 PMID: 36059674 PMCID: PMC9433783 DOI: 10.3389/fonc.2022.966529
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 5.738
Figure 1The work flow of this study.
Figure 2MR images of a 78-year-old woman with endometrial cancer. (A) Axial T2-weighted imaging is marked with a region of interest. (B) Axial diffusion-weighted imaging (b = 800 s/mm2). (C) Axial apparent diffusion coefficient imaging. (D) Axial contrast-enhanced T1-weighted imaging.
The comparisons of clinicopathologic characteristics between negative and positive LVSI patients in the training and test groups.
| Clinical features | Training group | Test group | ||||
|---|---|---|---|---|---|---|
| Negative LVSI (N = 188) | Positive LVSI (N = 38) | P | Negative LVSI (N = 97) | Positive LVSI (N = 16) | P | |
| Radscore | 0.12 (0.16) | 0.39 (0.17) | 0.001 | 0.11 (0.13) | 0.31 (0.18) | 0.001 |
| CA125 | 19.3 (13.1) | 34.4 (29.1) | 0.003 | 19.5 (13.3) | 38.4 (37.3) | 0.062 |
| Age | 56.0 (8.93) | 59.9 (9.44) | 0.022 | 56.1 (8.71) | 62.6 (11.9) | 0.048 |
| Tumor size | 15.3 (5.53) | 20.6 (8.62) | 0.001 | 15.4 (3.99) | 19.0 (5.57) | 0.023 |
| FIGO | ||||||
| IA | 165 (87.8%) | 23 (60.5%) | 0.001 | 79 (81.4%) | 10 (62.5%) | 0.166 |
| IB | 23 (12.2%) | 15 (39.5%) | 18 (18.6%) | 6 (37.5%) | ||
| Tumor type | ||||||
| Carcinosarcoma | 1 (0.5%) | 1 (2.6%) | 0.052 | 0 (0%) | 1 (6.3%) | 0.081 |
| Clear cell carcinoma | 1 (0.5%) | 1 (2.6%) | 2 (2.1%) | 0 (0%) | ||
| Endometrioid adenocarcinoma | 179 (95.2%) | 31 (81.6%) | 93 (95.9%) | 15 (93.8%) | ||
| Mixed adenocarcinoma | 2 (1.1%) | 2 (5.3%) | 0 (0%) | 0 (0%) | ||
| Serous adenocarcinoma | 5 (2.7%) | 3 (7.9%) | 2 (2.1%) | 0 (0%) | ||
| Tumor grade | 0.001 | 0.154 | ||||
| G1 | 129 (68.6%) | 15 (39.5%) | 64 (66.0%) | 8 (50.0%) | ||
| G2 | 42 (22.3%) | 8 (21.1%) | 22 (22.7%) | 3 (18.8%) | ||
| G3 | 8 (4.3%) | 8 (21.1%) | 7 (7.2%) | 4 (25.0%) | ||
| Others | 9 (4.8%) | 7 (18.4%) | 4 (4.1%) | 1 (6.3%) | ||
| Myometrial invasion | ||||||
| Non-MI and SMI | 165 (87.8%) | 23 (60.5%) | 0.001 | 79 (81.4%) | 10 (62.5%) | 0.166 |
| DMI | 23 (12.2%) | 15 (39.5%) | 18 (18.6%) | 6 (37.5%) | ||
CA125, cancer antigen 125; DMI, deep myometrial invasion; LVSI, lymph-vascular space invasion, SMI, superficial myometrial invasion.
Figure 3Feature selection by using LASSO. (A) The parameter lambda is chosen using 10-fold cross-validation via minimum criteria, which results in 10 features with non-zero coefficients. (B) LASSO coefficient profiles of the selected features. (C) Radiomics signature. (D) A co-occurrence network shows the correlations between radiomics signature and clinical features.
Figure 4The radiomics nomogram and calibration curves. (A) The radiomics nomogram is constructed by integrating radscore with patient age and CA125. The calibration curve of the radiomics nomogram for predicting LVSI in the training group (B) and the test group (C).
Diagnostic performance of the clinical risk factors, radscore, and radiomics nomogram in the training and test groups.
| Group | Index | AUC | 95% CI | SPE | SEN | NPV | PPV | P * | P # |
|---|---|---|---|---|---|---|---|---|---|
| Training | Clinical risk factors | 0.72 | 0.63-0.81 | 0.71 | 0.68 | 0.92 | 0.32 | 0.002 | – |
| Radscore | 0.88 | 0.81-0.94 | 0.74 | 0.92 | 0.98 | 0.42 | – | 0.002 | |
| Nomogram | 0.89 | 0.83-0.95 | 0.76 | 0.92 | 0.98 | 0.43 | 0.254 | 0.001 | |
| Test | Clinical risk factors | 0.71 | 0.57-0.86 | 0.81 | 0.56 | 0.92 | 0.33 | 0.239 | – |
| Radscore | 0.82 | 0.72-0.93 | 0.94 | 0.56 | 0.93 | 0.60 | – | 0.239 | |
| Nomogram | 0.85 | 0.75-0.94 | 0.96 | 0.56 | 0.93 | 0.69 | 0.116 | 0.104 |
AUC, area under the curve; CI, confidence interval; NPV, negative predictive value; PPV, positive predictive value; SEN, sensitivity; SPE, specificity.
*Compared with radscore; # compared with clinical risk factors by DeLong test.
Figure 5The decision curve shows that when the threshold probability is from 20% to 100%, the radiomics nomogram adds more net benefit than schemes of treat-all, treat-none, and radscore.